MOC Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.…
Industry Peers
BiotechnologyKey Statistics
About Molecure (WSE: MOC)
›
Molecure (WSE: MOC) is listed on Warsaw Stock Exchange, where its shares trade in PLN. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 5.430 PLN on 19 November 2026, down 35.5% over 52 weeks. Its 52-week range is 4.980 PLN to 9.040 PLN: the price is 39.9% below the high and 9.0% above the low.
Its market capitalisation is 134.25M PLN.
Molecure reports return on equity of -30.3%, an operating margin of -254.0% and revenue up 29.0% year over year.
It holds more cash than debt, a net cash position of 16.88M PLN. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 12.80 PLN is 135.7% above the current price.